Ionis Pharmaceuticals announced that the EMA's CHMP issued a positive opinion recommending an indication extension for its drug TRYNGOLZA for severe hypertriglyceridemia. This is a significant regulatory step towards expanding the drug's market in the EU, potentially making it the first RNA-targeted therapy for this condition in the region.
Ionis Pharmaceuticals received a positive opinion from the European Medicines Agency's CHMP for an indication extension of TRYNGOLZA to treat severe hypertriglyceridemia (sHTG) in adult patients with very high triglyceride levels. This is a crucial regulatory milestone, as it positions TRYNGOLZA to be the first and only RNA-targeted therapy for this specific sHTG population in the EU, following its recent approval in the U.S. The positive opinion, based on robust Phase 3 data showing significant triglyceride reduction and reduced pancreatitis events, comes ahead of schedule and suggests strong potential for final European Commission approval, expected in Q4 2026. This development is a long-term positive for Ionis, expanding its market reach and revenue potential in a significant therapeutic area, and could provide a short-term boost to investor confidence.